| Nicotine Regulation for Dual Users of E-cigarettes and Cigarettes (NCT06614504) | University of Vermont | 2024-11-01 |
| Non-Invasive Pulsed Radiofrequency for the Treatment of Neuropathic Pain (NCT06185816) | Stanford University | 2024-11-01 |
| Efficacy and Safety of N-Acetylcysteine Versus Alpha-Lipoic Acid in Colistin-Induced Nephrotoxicity (NCT06650384) | Ain Shams University | 2024-11-01 |
| Oxyhydrogen Nanobubble Infusion as a Complementary Therapy in Patients With Parkinsonism (NCT07466381) | dr. Siti Nurlaela, SpN | 2024-11-01 |
| Vincristine and Temozolomide in Combination With PEN-866 for Adolescents and Young Adults With Relapsed or Refractory Solid Tumors (NCT04890093) | National Cancer Institute (NCI) | 2024-10-31 |
| Neoadjuvant Lurbinectedin and Preoperative Radiation for Treating Soft Tissue Sarcomas (NCT06217536) | University of California, San Francisco | 2024-10-31 |
| Cannabidiol for Reducing Cigarette Use (NCT06218056) | University of California, Los Angeles | 2024-10-31 |
| Extension Study to Evaluate the Long-Term Safety and Tolerability of MBX 2109 in Patients With Hypoparathyroidism (NCT06531941) | MBX Biosciences | 2024-10-31 |
| A Trial Evaluating Efficacy of AGA2118 in PostMenopausal Women wIth Low Bone MasS (ARTEMIS) (NCT06577935) | Angitia Biopharmaceuticals | 2024-10-31 |
| Safety and Efficacy of Mitoxantrone Hydrochloride Liposome Based DCMG Regimen for R/R AML (NCT06741722) | Beijing 302 Hospital | 2024-10-31 |
| Intranasal Insulin for Posttraumatic Stress Disorder (NCT04044534) | VA Connecticut Healthcare System | 2024-10-31 |
| Fezolinetant for the Improvement of Vasomotor Symptoms in Breast Cancer Patients Taking Endocrine Therapy, VENT Trial (NCT06617455) | University of Michigan Rogel Cancer Center | 2024-10-31 |
| A Study to Evaluate the Efficacy and Safety of Combination Therapy of BRII-179, BRII-835 and PEG-IFNα in Participants With Chronic Hepatitis B Virus (HBV) Infection (ENHANCE) (NCT06650852) | Brii Biosciences Limited | 2024-10-31 |
| A Study of DM005 in Patients With Advanced Solid Tumors (NCT06515990) | Doma Biopharmaceutical（Suzhou）Co., Ltd. | 2024-10-31 |
| Evaluation of the Possible Safety and Efficacy of Dapagliflozin in the Prophylaxis of Doxorubicin-Induced Cardiotoxicity (NCT06427226) | Tanta University | 2024-10-31 |
| The Androtriol Injection for the Treatment of Acute Ischemic Stroke (NCT06679322) | Beijing Tiantan Hospital | 2024-10-31 |
| A Prospective, Randomized, Controlled Clinical Study on the Prevention of Chemotherapy Related Myelosuppression in Patients with Ewing's Sarcoma Using Trilaciclib (NCT06699472) | Fudan University | 2024-10-31 |
| Anlotinib Plus Benmelstobart and AG in First-line Treatment of Advanced Metastatic Pancreatic Cancer (ALTER-PA-001) (NCT06621095) | RenJi Hospital | 2024-10-30 |
| Tirzepatide for Weight Loss Intervention in Early-Stage Hormone Receptor Positive/HER2 Negative Breast Cancer (NCT06518837) | Rutgers, The State University of New Jersey | 2024-10-30 |
| Molecular Subtype Combined with Early Minimal Residual Disease to Optimize the Treatment of Newly Diagnosed Acute Myeloid Leukemia (NCT06652685) | Ruijin Hospital | 2024-10-30 |
| A Study of Valemetostat Tosylate Plus Pembrolizumab Versus Pembrolizumab Alone in First-Line NSCLC Without Actionable Genomic Alterations (NCT06644768) | Daiichi Sankyo | 2024-10-30 |
| Efficacy and Safety of Obefazimod in Subjects With Moderately to Severely Active Crohn's Disease (NCT06456593) | Abivax S.A. | 2024-10-30 |
| Safety and Efficacy Trial of a Targeted PSMA Fluorescent Contrast Agent (DGPR1008) for Intraoperative Imaging of Prostate Cancer (NCT07024030) | Haitao Niu, MD | 2024-10-30 |
| REscuing Bone Marrow Function in Patients with AplaStic AnaEmia and Bone Marrow FaiLure Post AllogEneiC Transplantation 2 (NCT06607367) | Melbourne Health | 2024-10-30 |
| Spironolactone Improved Children With Gene Mutations Related to NCOR (NCT06678685) | Qilu Hospital of Shandong University | 2024-10-30 |
| A Study to Assess the Effect of AZD0780 on Ambulatory Blood Pressure (NCT06692764) | AstraZeneca | 2024-10-30 |
| Tuvusertib Combined With Niraparib or Lartesertib in Participants With Epithelial Ovarian Cancer (DDRiver EOC 302) (NCT06433219) | EMD Serono Research & Development Institute, Inc. | 2024-10-30 |
| Demethylating Agents Combined With Venetoclax for High-risk T-cell Lymphoblastic Lymphoma/Leukemia Post-Transplant Relapse Prevention (NCT06686108) | Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine | 2024-10-30 |
| "The Effect of Memantine on the Prevention and Amelioration of Paclitaxel-induced Toxicity in Breast Cancer Patients" (NCT06679387) | Ain Shams University | 2024-10-30 |
| Zanubrutinib Plus Rituximab as Front-line Treatment for Mucosa-associated Lymphoid Tissue Lymphoma (MALT) (NCT06647732) | Sun Yat-sen University | 2024-10-30 |
| GLP-1 Receptor Agonists Post-Bariatric Surgery (GRABS) Pilot Trial (NCT06162715) | Vanderbilt University Medical Center | 2024-10-30 |
| Study to Evaluate the Safety and Efficacy of Tapinarof in Adults With Palmoplantar Keratoderma (NCT06561321) | Indiana University | 2024-10-30 |
| A Study of Safety and Tolerability of Multiple Doses of HRS-7535 in Obese Subjects (NCT06621316) | Shandong Suncadia Medicine Co., Ltd. | 2024-10-30 |
| A Study of HS-20106 to Treat Anemia Due to Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (NCT06594965) | Hansoh BioMedical R&D Company | 2024-10-30 |
| Phase II Study of Sonrotoclax Combined With Chemotherapy in the Treatment of Newly Diagnosed Acute Myeloid Leukemia (NCT06497062) | Shanghai Jiao Tong University School of Medicine | 2024-10-30 |
| Clinical Trial of Zuoqing SAN in Treating Ulcerative Colitis (NCT06667934) | The Second Affiliated Hospital of Anhui University of Traditional Chinese Medicine | 2024-10-30 |
| Phase I/II Clinical Study to Evaluate VB15010 Tablets in Patients With Advanced Solid Tumors (NCT06819215) | Zhejiang Yangli Pharmaceutical Technology Co., Ltd. | 2024-10-30 |
| Chlorophyllin for Reducing Oral Mucositis in Total Body Irradiation Prior to Transplant (NCT07709195) | Tata Memorial Centre | 2024-10-30 |
| NALIRIFOX Combined With PD-1 Sequential Radiotherapy Versus NALIRIFOX as Conversion Therapy of Locally Advanced Pancreatic Cancer (NCT06669078) | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | 2024-10-30 |
| A Multicenter, Randomized, Controlled Trial of Prednisone Combined With Ursodeoxycholic Acid in the Treatment of Primary Biliary Cholangitis With Moderate to Severe Interface Hepatitis Characteristics (NCT06591468) | Han Ying | 2024-10-30 |
| A Study of Avutometinib + Defactinib in Recurrent Low-Grade Serous Ovarian Cancer in Japanese Patients (NCT06682572) | Verastem, Inc. | 2024-10-30 |
| Silmitasertib (CX-4945) in Combination With Chemotherapy for Relapsed Refractory Solid Tumors (NCT06541262) | Milton S. Hershey Medical Center | 2024-10-30 |
| Neoadjuvant Radiotherapy for Locally Advanced Unresectable Thymoma (NCT06924619) | Second Affiliated Hospital, Zhejiang University, School of Medicine | 2024-10-30 |
| Individualised Dose Optimisation of Ganciclovir in Immunocompromised Children Trial (ID-MAGIC) (NCT06574789) | Murdoch Childrens Research Institute | 2024-10-29 |
| A Study Evaluating Efficacy and Safety of VX-993 for Acute Pain After a Bunionectomy (NCT06619847) | Vertex Pharmaceuticals Incorporated | 2024-10-29 |
| Neurobiological Drivers of Mobility Resilience: The Dopaminergic System - Supplemental Open-Label Arm (NCT06587217) | University of Michigan | 2024-10-29 |
| Efficacy and Safety of HB-1 for Panic Disorder (NCT06483789) | HB BioTech, LLC | 2024-10-29 |
| A Study of Mosliciguat in PH-ILD (NCT06635850) | Pulmovant, Inc. | 2024-10-29 |
| To Evaluate Dose and Safety of NanoEcho Particle-1 Using NanoEcho Imaging Device Examinations of Rectal Lymph Nodes in Healthy Volunteers and Rectal Cancer Patients. (NCT06693375) | NanoEcho AB | 2024-10-29 |
| Effect of Goal-Oriented Albumin Infusion on Postoperative Complication Management in Gastric Cancer Surgery (NCT07119463) | The First Hospital of Jilin University | 2024-10-29 |
| Biliary Anastomosis in Living Donor Liver Transplant With Amniotic Tissue (NCT07102550) | Choon Hyuck David Kwon | 2024-10-29 |
| A Study of Lifileucel (Tumor-infiltrating Lymphocytes) in Adults With Advanced Endometrial Cancer. (NCT06481592) | Iovance Biotherapeutics, Inc. | 2024-10-29 |
| TReatment of ADC-Refractory Breast CancEr With Dato-DXd or T-DXd: TRADE DXd (NCT06533826) | Ana C Garrido-Castro, MD | 2024-10-29 |
| CROSSOVER STUDY OF ON-DEMAND PREP FORMULATIONS COMPARING RECTAL AND ORAL TENOFOVIR (NCT06560684) | National Institute of Allergy and Infectious Diseases (NIAID) | 2024-10-29 |
| Phase 2 Study Evaluating Rapcabtagene Autoleucel in Participants With Diffuse Cutaneous Systemic Sclerosis (NCT06655896) | Novartis Pharmaceuticals | 2024-10-29 |
| Efficacy and Safety of Skincare Serum and Cream for Anti-aging of Facial Skin (NCT06638905) | Goldman, Butterwick, Fitzpatrick and Groff | 2024-10-28 |
| IMPACT 360 for Parkinson's Disease (NCT07443293) | University of British Columbia | 2024-10-28 |
| A Single-center, Self-controlled, Prospective Case Series Pilot Study to Assess the Effect of Lamivudine (3TC) on Neurocognitive Impairment Biomarkers and Type-I IFN (Interferon)-Stimulated Genes in the Plasma of Patients With Mild Cognitive Impairment (MCI) (NCT06519357) | Fundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promoción de la Salud y la Ciencia | 2024-10-28 |
| Examining Intranasal Oxytocin Augmentation of Brief Couples Therapy for Veterans With PTSD (NCT06194851) | VA Office of Research and Development | 2024-10-28 |
| Efficacy and Safety of Dimethyl Fumarate Among Patients with Mild Cognitive Impairment and Dementia Due to Alzheimer's Disease (NCT06850597) | Medical University of Lodz | 2024-10-28 |
| A Phase 2b, Dose-range Finding Study of the Efficacy and Safety of Multiple Doses of Aleniglipron (GSBR-1290) in Participants Living With Obesity or Overweight With at Least One Weight-related Comorbidity (NCT06693843) | Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics | 2024-10-28 |
| Avutometinib and Defactinib in Diffuse Gastric Cancer (NCT06487221) | Ryan H. Moy, MD, PhD | 2024-10-28 |
| Apimostinel + Automated Neurocognitive Training for Depression (NCT06400121) | Rebecca Price | 2024-10-28 |
| Sacituzumab Govitecan in Combination With Cisplatin in Platinum Sensitive Recurrent Ovarian and Endometrial Cancer (NCT06040970) | Icahn School of Medicine at Mount Sinai | 2024-10-28 |
| Effects of Low-intensity Transcranial Magnetic Stimulation on Major Depressive Disorder, and on 5-hydroxyindoleacetic Acid and Brain-derived Neurotrophic Factor Levels (NCT06667180) | Universidad de Guanajuato | 2024-10-28 |
| Clinical Trial to Evaluate the Safety and Efficacy of JTM201 to Treat Moderate or Severe Glabellar Lines (NCT06246552) | Jetema USA Inc. | 2024-10-26 |
| A Study of LY4100511 (DC-853) in Adult Participants With Moderate-to-Severe Plaque Psoriasis (NCT06602219) | DICE Therapeutics, Inc., a wholly owned subsidiary of Eli Lilly and Company | 2024-10-25 |
| Cannabidiol for Reducing Drinking in Alcohol Use Disorder (NCT05159830) | Hôpital le Vinatier | 2024-10-25 |
| Reducing Frailty for Older Cancer Survivors Using Supplements II (NCT06068543) | University of Rochester | 2024-10-25 |
| A Study Comparing Abemaciclib Plus Temozolomide to Temozolomide Monotherapy in Children and Young Adults With High-grade Glioma Following Radiotherapy (NCT06413706) | Eli Lilly and Company | 2024-10-25 |
| A Study of Andecaliximab in Participants With Fibrodysplasia Ossificans Progressiva (FOP) (NCT06508021) | Ashibio Inc | 2024-10-25 |
| Nutritional Supplementation in Head and Neck Cancers (NCT05379712) | AHS Cancer Control Alberta | 2024-10-25 |
| Turkey Tail Mushroom for Treating Post-Menopausal Women With HER2-Negative ER-Positive Breast Cancer Undergoing Surgery (NCT06450873) | Mayo Clinic | 2024-10-25 |
| The Effects of Bio Gelee Royale Forte on Immune Health in Healthy Adults (NCT06573814) | Medex d.o.o. | 2024-10-25 |
| ALS Phase II Study of NX210c (NCT06365216) | Axoltis Pharma | 2024-10-25 |
| A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of the Efficacy and Safety of Qifangfeixian Granules in the Treatment of Connective Tissue Disease-Associated Interstitial Lung Disease (CTD-ILD) (NCT06674148) | Huilan Zhang | 2024-10-25 |
| Integrative Breathwork Intervention for Chronic Pain (NCT06546956) | University of Florida | 2024-10-24 |
| A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), and Antitumor Activity of ALK201 in Participants With Advanced Solid Tumors (NCT06656390) | Shanghai Allink Biotherapeutics Co., Ltd. | 2024-10-24 |
| Personalized Antisense Oligonucleotide for A Single Participant With ATN1 Gene Mutation (NCT07084311) | n-Lorem Foundation | 2024-10-24 |
| Safety, Tolerability, and Pharmacokinetics of Exidavnemab in Patients With Parkinson's Disease and Patients With Multiple System Atrophy (NCT06671938) | BioArctic AB | 2024-10-24 |
| Phase 1/2 Clinical Study of HY07121 Powder for Solution for Infusion in Patients With Advanced Solid Tumors (NCT06639256) | Sichuan Huiyu Pharmaceutical Co., Ltd | 2024-10-24 |
| Safety and Pharmacodynamic Effects of BIIB122 in Participants With LRRK2-Associated Parkinson's Disease (LRRK2-PD) (NCT06602193) | Denali Therapeutics Inc. | 2024-10-24 |
| Gemcitabine Hydrochloride, Cisplatin, Nab-Paclitaxel, and Durvalumab in Treating Patients With Locally Advanced or Metastatic Gallbladder Cancer (NCT06591650) | Fudan University | 2024-10-24 |
| A Study to Learn About the Treatment LTP001 in Healthy Participants (Part A) and in Participants With PAH (Part B) (NCT06649110) | Novartis Pharmaceuticals | 2024-10-24 |
| Standard Immunosuppressive Therapy Combined With Romiplostim N01 as First-line Treatment for Severe Aplastic Anemia (NCT06613880) | Institute of Hematology & Blood Diseases Hospital, China | 2024-10-24 |
| Benmelstobart Combined With Radiochemotherapy as Neoadjuvant Treatment Iin ESCC (NCT06637163) | Shanghai Zhongshan Hospital | 2024-10-24 |
| Intratumoral INT230-6 Followed by Neoadjuvant Immuno-chemotherapy in Patients With Early TNBC. INVINCIBLE-4-SAKK (NCT06358573) | Swiss Cancer Institute | 2024-10-24 |
| Uterine Preservation Via Lifestyle Transformation (NCT05903131) | Washington University School of Medicine | 2024-10-24 |
| A Comparative Dose-finding Study of RS-113 in Patients With Metastatic Castration-resistant Prostate Cancer (NCT07553988) | R-Pharm International, LLC | 2024-10-24 |
| Study of ZG005 Combined With Bevacizumab Versus Sintilimab Combined With Bevacizumab in Advanced Hepatocellular Carcinoma (NCT06558227) | Suzhou Zelgen Biopharmaceuticals Co.,Ltd | 2024-10-24 |
| Study of JK06 in Patients With Unresectable Locally Advanced or Metastatic Cancer (NCT06667960) | Salubris Biotherapeutics Inc | 2024-10-23 |
| Sintilimab Plus AVD in Pediatric Low/Moderate Risk Hodgkin Lymphoma: A Phase II Study (NCT06848569) | Sun Yat-sen University | 2024-10-23 |
| Arsenous Acid for Refractory Triple-Negative Breast Cancer (NCT06678048) | Sun Yat-sen University | 2024-10-23 |
| Study With Mosunetuzumab and Zanubrutinib in R/R Follicular Lymphoma Patients (NCT06492837) | Fondazione Italiana Linfomi - ETS | 2024-10-23 |
| Testing the Use of Combination Therapy in Patients With Persistent Low Level Acute Myeloid Leukemia (AML) Following Initial Treatment (NCT05628623) | Eastern Cooperative Oncology Group | 2024-10-23 |
| A Safety and Efficacy Study of ARGX-119 in Adult Patients With Amyotrophic Lateral Sclerosis (ALS) (NCT06441682) | argenx | 2024-10-23 |
| Development and Evaluation of Computerized Chemosensory-Based Orbitofrontal Networks Training for Treatment of Pain (CBOT-P) (NCT06671132) | Evon Medics LLC | 2024-10-23 |
| FIH Trial of VERT-002 in Patients With Locally Advanced or Metastatic Solid Tumors With MET Alterations (NCT06669117) | Pierre Fabre Medicament | 2024-10-22 |
| A Study of Lower Radiotherapy Dose to Treat Children With CNS Germinoma (NCT06368817) | Children's Oncology Group | 2024-10-22 |
| Safety and Immunogenicity of Two Dose Levels of OVX836 Influenza Vaccine as a Booster on Participants Previously Administered With OVX836 (NCT06582277) | Osivax | 2024-10-22 |